Trial Profile
An Open-Label Study to Assess the Effect of First-Line Treatment With Avastin in Combination With Standard Therapy on Progression-Free Survival in Patients With Metastatic Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2a; Vinblastine
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Roche
- 31 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Mar 2010 Planned number of patients changed from 180 to 25 as reported by ClinicalTrials.gov.